DPP4 and type 2 diabetes mellitus: In a 5-year follow-up trial, it was found that newly diagnosed T2D patients who received early combination therapy with metformin and vildagliptin, a DPP-4 inhibitor, had better long-term glycemic control compared to those who only received early monotherapy with metformin (102).